Probenecid is a chemosensitizer in cancer cell lines.

Resistance and toxicity are the major barriers to successful cancer chemotherapies. Developing molecules that reduce drug resistance and improve antineoplastic effects is of great interest for cancer research; ideally, these substances should not affect the pharmacodynamics of the chemotherapeutic agent while providing a synergistic antineoplastic effect. In this study, we tested in vitro co-administration of the antineoplastic agents cisplatin or paclitaxel with probenecid, an anion channel inhibitor, in a panel of cancer cell lines to determine the cytotoxicity and synergistic effects of these drug combinations. In addition, we measured the clonogenicity and apoptotic index in these cells. We observed a synergistic interaction between probenecid and the chemotherapeutic agents, and increasing doses of probenecid resulted in a significant decrease in the effective doses of the chemotherapeutic agents. For the antineoplastic agent and probenecid combinations, we found increased cell death, reduced colony formation, and a higher number of apoptotic cells, compared with treatment of cisplatin or paclitaxel alone. Further research is necessary to elucidate the molecular mechanisms by which the synergistic effect occurs. If these synergistic effects can be reproduced in vivo, the co-administration of probenecid with different chemotherapeutic agents may provide a valid treatment in patients with chemotherapy resistance.
AuthorsDenise Campos-Arroyo, Juan Carlos Martínez-Lazcano, Jorge Melendez-Zajgla
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 69 Issue 2 Pg. 495-504 (Feb 2012) ISSN: 1432-0843 [Electronic] Germany
PMID21861129 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Pharmaceutic
  • Antineoplastic Agents
  • Paclitaxel
  • Probenecid
  • Cisplatin
  • Adjuvants, Pharmaceutic (pharmacology)
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Cisplatin (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • HeLa Cells
  • Humans
  • Microscopy, Fluorescence
  • Neoplasms (drug therapy, pathology)
  • Paclitaxel (pharmacology)
  • Probenecid (pharmacology)
  • Tumor Stem Cell Assay

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: